Cassava Sciences | PTIE - Pre Tax Profit


Cassava Sciences reported $-10.81M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Abbott USD 2.39B 27M Mar/2026
Amgen USD 2.08B 570M Mar/2026
Biogen USD 647.3M 269.6M Jun/2026
Cara Therapeutics USD -6.8M 1.9M Mar/2026
Cassava Sciences USD -10.81M 33.41M Sep/2025
Eisai JPY 25.28B 33.22B Jun/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Geron USD -3.64M 27.5M Mar/2026
J&J USD 8.66B 839M Jun/2026
Merck USD -3.53B 6.95B Mar/2026
Novartis USD 4.27B 430M Jun/2026
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD -653M 5.84B Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026